IPCA Laboratories Q1 FY27: Revenue Growth Accelerates, EBITDA Margin Guidance Raised to 23%

Ipca Laboratories Ltd. delivered a strong performance in the first quarter of FY2026-27, with growth across its domestic formulations, export, generic and API businesses. During its Q1 FY27 earnings call held on August 14, 2026, management highlighted strong business momentum, improving profitability and a positive outlook for the full financial year.

The company has also raised its FY27 growth and margin expectations, with consolidated business growth now expected at 14%-16%, compared with the earlier guidance of 12%-13%. Consolidated EBITDA margin guidance has been increased from 22% to approximately 23%.

Domestic Formulations Business Grows 13%

Ipca’s domestic formulation business recorded approximately 13% growth in Q1 FY27, reaching around ₹1,082 crore, compared with ₹961 crore in Q1 FY26.

The company’s market position remained around 16, according to IQVIA, while market share improved marginally to approximately 2.08% from 2.07% in March 2026.

Both chronic and acute businesses outperformed the Indian Pharmaceutical Market (IPM). Chronic growth was approximately 17.2%, while acute growth stood at around 8.9%, compared with IPM growth of approximately 4.5% in the acute segment.

Management said the domestic business continues to see encouraging trends, particularly in chronic therapies.

Strong Growth Across Key Therapeutic Segments

Several of Ipca’s domestic therapeutic segments recorded healthy growth during the quarter.

Pain management, including rheumatoid arthritis and osteoarthritis, grew approximately 13%. Cardiovascular and antidiabetic products increased around 17%.

The CNS segment grew nearly 19%, while dermatology increased around 17%. Urology recorded approximately 25% growth, and ophthalmology grew around 17%.

The company’s cough and cold business grew around 9%, while antibacterials recorded approximately 1% growth.

The antimalarial segment declined about 24% during the quarter and has now become relatively small, accounting for only around 1% of the company’s overall business.

Export Business Jumps 34%

Ipca’s overall export business grew approximately 34% in Q1 FY27 to around ₹603 crore, compared with ₹450 crore in the corresponding quarter of the previous year.

Promotional branded markets in the rest-of-the-world segment grew around 16% to ₹143 crore from ₹124 crore.

The generic business excluding institutional tenders grew approximately 27%, reaching around ₹340 crore from ₹268 crore in Q1 FY26. Institutional generic business increased sharply to approximately ₹111.75 crore from ₹58 crore.

However, management clarified that the exceptionally high institutional growth was partly due to approximately ₹40 crore of shipments that were scheduled for March but were actually shipped in April because of logistics and shipping delays. Normalized institutional growth is therefore expected to remain in the single digits.

Europe Emerges as a Major Generic Growth Driver

The European business was one of the strongest contributors to generic growth.

Management said the European business grew approximately 70%, with revenue increasing from around ₹33 crore to ₹137 crore.

The U.S. business also recorded approximately 8% growth, while Canada saw a minor decline.

Ipca expects approximately 3-4 product launches per year under its own label in the U.S., while Unichem is expected to launch a similar number. Overall, the combined pipeline could result in around 7-8 launches annually across Ipca and Unichem.

The company is also progressing with API source changes and cost-reduction initiatives, with some applications already filed with the U.S. FDA.

Management believes the U.S. business could potentially deliver growth in the range of 15%-17% over the coming period, based on the current portfolio and pipeline.

Unichem Laboratories Shows Improvement

The performance of Unichem Laboratories was another important focus of the earnings call.

Unichem’s U.S. business grew approximately 27% in Q1. The Ipca portfolio sold through Unichem grew strongly, while Unichem’s own portfolio grew approximately 9%.

Brazil delivered particularly strong growth of around 52%, while the Acacia ROW business increased from approximately ₹8 crore to ₹17 crore.

Unichem’s API business also increased from around ₹33-34 crore to approximately ₹58 crore, representing growth of around 73%.

Management has not yet revised its earlier Unichem guidance and said it would wait for a few more quarters before changing its expectations.

Margin Expansion Despite Higher Input and Logistics Costs

One of the key highlights of the quarter was the improvement in profitability despite higher material and logistics costs.

Consolidated EBITDA margin improved to 22.88% in Q1 FY27 from 18.39% in Q1 FY26, an improvement of approximately 4.49 percentage points.

Consolidated EBITDA increased to approximately ₹638 crore from ₹425 crore, representing an increase of around 50%. Standalone EBITDA margin also improved to approximately 26%.

Management said the improvement was not primarily driven by material-cost savings. Instead, higher revenue helped reduce personnel and manufacturing costs as a percentage of sales.

On a consolidated basis, material costs declined by approximately 1.35% as a percentage of sales, personnel costs declined around 1.5%, and manufacturing and other costs declined approximately 1.19%.

Logistics Costs Remain a Challenge

The pharmaceutical company continues to face volatility in material prices and international freight costs.

Management highlighted container shortages and rising freight rates, particularly for shipments to South America, the U.S. and Europe.

According to the company, some South American container freight rates have increased from around $3,000 to $9,000-$10,000. U.S. container rates have moved from approximately $7,000-$7,500 to around $12,500-$13,000, while European rates have risen from around $3,000 to approximately $5,500.

Despite these challenges, management does not currently expect significant margin pressure and expects material costs relative to sales to moderate going forward.

India Field Force Expansion Nears Completion

Ipca currently has approximately 7,000 medical representatives in its field force.

Management said the expansion is largely complete, although around 200 additional people may be added during the year for new divisions.

The company therefore does not expect a major increase in its overall field-force size during FY27.

Major Capex Planned for FY27

Ipca is continuing to invest in manufacturing capacity, research and development, and new facilities.

The company expects approximately ₹700-800 crore of capital expenditure during the current financial year.

Investments are being made in Pithampur for controlled-release and extended-release formulations, while additional API capacity is being developed at Dewas and Wardha. The company is also investing in continuous-process capabilities for intermediates.

These investments are aimed at supporting future growth in the U.S. and European markets as well as expanding API capacity.

Debt Position Remains Comfortable

Ipca has significantly reduced its foreign-currency debt exposure.

Management said the company had approximately $50 million of dollar loans during the previous financial year and prepaid those loans before March 2026.

Current debt is approximately ₹193 crore, with no short-term borrowings. Management expects around ₹70 crore of term-loan debt to remain at the end of the current financial year, with repayment scheduled for the following financial year.

The company indicated that it currently has more cash than its total outstanding loans.

Biotech and Biosimilars Could Become a Long-Term Growth Driver

Ipca is increasing its investment in biotechnology and biosimilars.

The company currently has around seven biosimilar candidates in its pipeline and has the R&D capacity to work on approximately three to four products annually.

Two products have already reached the engineering-batch stage, with results reported to be in line with expectations. Validation work is underway, followed by formulation development, stability studies and clinical trials.

Ipca expects to invest approximately ₹100 crore during the current year in biotech pilot facilities and additional R&D.

Most of the biosimilar candidates are for products that have already lost patent protection, while one candidate is being targeted around patent expiry and is described by management as a large product opportunity.

The company is targeting global markets, including the U.S. and Europe. Management expects clinical activities to begin from the next financial year, with potential revenue contribution from these products in the FY29-FY30 timeframe.

Long-Term Margin Potential

Management also outlined its longer-term margin expectations.

Standalone Ipca EBITDA margins, currently around 26%, could potentially reach approximately 30% over the longer term.

For the consolidated business, management indicated that EBITDA margins could potentially reach around 25%-26% over the next two to three years, as subsidiaries such as Unichem improve their performance.

Ipca Laboratories Outlook for FY27

The company’s FY27 outlook has become more optimistic following the strong Q1 performance.

Management has raised consolidated business growth guidance from 12%-13% to 14%-16%.

Consolidated EBITDA margin guidance has also been raised from 22% to around 23%.

The upgrade reflects better-than-expected performance across the domestic business, generics, exports and API operations.

Domestic growth is expected to remain strong, with management retaining its earlier 12%-13% growth expectation for the India business.

Ipca Laboratories’ Q1 FY27 earnings call highlighted several positive developments:

• Domestic formulations grew around 13%.
• Export business increased approximately 34%.
• Generic business excluding institutional business grew around 27%.
• Europe emerged as a major growth driver.
• API business grew around 30%.
• Consolidated EBITDA margin improved significantly.
• FY27 revenue growth guidance was raised to 14%-16%.
• Consolidated EBITDA margin guidance was raised to around 23%.
• Unichem continued to show improvement across the U.S., Brazil, Europe and API businesses.
• ₹700-800 crore of FY27 capex is planned.
• The company is building a seven-product biosimilar pipeline.
• Debt remains relatively low, with no short-term borrowings.
• Long-term EBITDA margin potential has improved as the company expects subsidiaries to scale.

Conclusion

Ipca Laboratories’ Q1 FY27 commentary points to a broad-based improvement across its business rather than dependence on a single growth segment. Domestic formulations, exports, generics, APIs and Unichem all contributed to the positive momentum.

The increase in FY27 growth guidance to 14%-16% and the improvement in EBITDA margin guidance to approximately 23% indicate management’s confidence in the current trajectory. At the same time, rising freight costs, raw-material volatility and execution of the company’s large capex programme remain important factors to monitor.